Time filter

Source Type

Tur F.T.,Sb Izmir Tepecik Training And Research Hospital | Tur F.T.,Tepecik Training and Research Hospital | Aksay E.,Sb Izmir Tepecik Training And Research Hospital | Aksay E.,Dokuz Eylül University | And 2 more authors.
European Journal of Integrative Medicine | Year: 2015

Introduction: The popularity of acupuncture as a complementary treatment for obesity has been increasing. Its role in body weight reduction (BWR) in obese patients is promising, but no studies have yet examined its effects on glycosylated hemoglobin (HbA1c) levels. Our aim was to investigate whether acupuncture reduces HbA1c levels, weight and BMI in obese patients. Methods: Patients presenting to the acupuncture clinic for weight loss with a BMI greater than 25 were enrolled into this prospective before and after study. Each patient received 20 sessions of acupuncture therapy delivered by a certified acupuncturist. Weight, BMI and HbA1c levels were measured both before and after the full course of acupuncture treatments for comparison. Comorbid conditions that influence the development of obesity such as diabetes, age and postmenopausal state were reviewed. Results: A total of 42 patients were enrolled into the study mean age of 42.6 ± 11.9 years. Of the 42 patients completing all 20 sessions, the average of body weight was 99.7 ± 21.6 and BWR was 6.9 ± 4.5kg (95% CI, 5.5-8.3; p < 0.001). At the beginning and end of the acupuncture treatment, mean BMI was 38.1 ± 7.6 kg/m2 (25.2-59.5 kg/m2) and 35.4 ± 7.2 kg/m2 (95% CI, 2.1-3.2; p < 0.001), respectively. The mean HbA1c level before and after acupuncture was 5.9 ± 0.8% and 5.7 ± 0.4% (95% CI, 0.1-0.4; p = 0.015), respectively. Conclusions: 20 sessions of acupuncture treatment for obese patients may confer reductions in weight, BMI and HbA1c levels. © 2015 Elsevier GmbH.

Degirmenci M.,Ege University | Karaca B.,Ege University | Gorumlu G.,Ege University | Durusoy R.,Ege University | And 7 more authors.
Medical Oncology | Year: 2010

Recent phase III trials have proven the fact that adding bevacizumab to irinotecan plus infusional 5-fluorouracil (5-FU)/leucovorin (LV) should be preferred as a first-line treatment for metastatic colorectal cancer (mCRC). But, since the data regarding bevacizumab administered together with capecitabin, an oral fluoropyrimidine, and irinotecan in patients with mCRC is limited, we aimed to analyse the efficacy and safety of bevacizumab with capecitabine plus irinotecan (BEV-CAPIRI) regimen in mCRC patients. Records of patients treated with BEV-CAPIRI regimen between January 2005 and March 2008 were reviewed. Efficacy data regarding response rates (RR) as well as safety data were collected. Progression free survival (PFS) and overall survival (OS) analyses were done by using the Kaplan-Meier method. A total number of 53 metastatic colorectal cancer patients were treated with BEV-CAPIRI regimen. The median age of this population was 57.3 ± 11.5 (range 29-78). The treatment was well tolerated. The RR was 43.3%, while 30.1% of the patients achieved stable disease (SD). Median PFS and OS were 12.6 ± 1.4 and 20.6 ± 1.7 months, respectively. However, median OS was 21.3 months for male and 14.6 months for female patients. In addition, median OS and PFS was 25.3 months and 16.2 months for the patients who received BEV-CAPIRI as first-line treatment, respectively, and for the other patients it was 15.2 months and 10.2 months, respectively. In conclusion, BEV-CAPIRI is an effective and well-tolerated alternative regimen for mCRC, leading to disease control in a vast majority of patients with mCRC. © 2009 Humana Press Inc.

Loading SB Izmir Tepecik Training and Research Hospital collaborators
Loading SB Izmir Tepecik Training and Research Hospital collaborators